Results 1 to 10 of about 44,843 (147)

Full-profile pharmacokinetics, anticancer activity and toxicity of an extended release trivalent PEGylated irinotecan prodrug

Acta Pharmaceutica Sinica B, 2023
Irinotecan is an anticancer topoisomerase I inhibitor that acts as a prodrug of the active metabolite, SN-38. Unfortunately, the limited utility of irinotecan is attributed to its pH-dependent stability, short half-life and dose-limiting toxicity.
Dong Sun, John Paul Fawcett, Jingkai Gu   +2 more
exaly   +3 more sources

Economic evaluation of the second-line regimen of liposome irinotecan (II) combined with 5-FU/LV versus placebo combined with 5-FU/LV for locally advanced or metastatic pancreatic ductal adenocarcinoma in China. [PDF]

PLoS ONE
BackgroundThe cost-effectiveness of liposome irinotecan (II) (HR070803) in combination with 5-fluorouracil and leucovorin as a treatment for patients with locally advanced or metastatic pancreatic ductal adenocarcinoma offering a potential new standard ...
Jinlong Huang, Hanyun Ye, Jingyang Lin, Dan Luo, Ping Huang, Xiaochun Zheng   +5 more
doaj   +2 more sources

Hepatic ROS Mediated Macrophage Activation Is Responsible for Irinotecan Induced Liver Injury

Cells, 2022
Irinotecan is the first line chemotherapy drug used for treatment of metastatic colorectal cancer worldwide. There is increasing evidence suggesting that liver damage, including steatosis and steatohepatitis, can be caused during the treatment involving ...
Bohao Liu, Cong Ding, Wenbin Tang, Chen Zhang, Yiying Gu, Zhiqiang Wang, Tingzi Yu, Zhuan Li   +7 more
doaj   +1 more source

Contribution of HIF-1α/BNIP3-mediated autophagy to lipid accumulation during irinotecan-induced liver injury

Scientific Reports, 2023
Irinotecan is a topoisomerase I inhibitor which has been widely used to combat several solid tumors, whereas irinotecan therapy can induce liver injury.
Congjian Shi, Zhenghong Zhang, Renfeng Xu, Yan Zhang, Zhengchao Wang   +4 more
doaj   +1 more source

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer

CPT: Pharmacometrics & Systems Pharmacology, 2021
Liposomal irinotecan is a liposomal formulation of irinotecan, which prolongs circulation of irinotecan and its active metabolite SN‐38. A population pharmacokinetic (PK) model was developed based on data from seven studies (N = 440).
Karl Brendel, Tanios Bekaii‐Saab, Patrick M Boland, Farshid Dayyani, Andrew Dean, Teresa Macarulla, Fiona Maxwell, Kabir Mody, Anna Pedret‐Dunn, Zev A Wainberg, Bin Zhang   +10 more
doaj   +1 more source

Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report

Case Reports in Oncology, 2021
Irinotecan hydrochloride (irinotecan) is a chemotherapeutic agent used in the treatment of solid tumors. In addition to severe neutropenia and delayed diarrhea, irinotecan causes cholinergic syndrome, characterized by abdominal pain and acute diarrhea ...
Kazuki Uchiyama, Yoshitaka Saito, Yoh Takekuma, Satoshi Yuki, Mitsuru Sugawara   +4 more
doaj   +1 more source

Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line

Frontiers in Oncology, 2021
Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. Irinotecan is widely used as a chemotherapeutic drug to treat CRC. However, the mechanisms of acquired resistance to irinotecan in CRC remain inconclusive.
Zhuo-Xun Wu, Yuqi Yang, Leli Zeng, Leli Zeng, Harsh Patel, Letao Bo, Lusheng Lin, Zhe-Sheng Chen   +7 more
doaj   +1 more source

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma

Cancer Medicine, 2023
Background Subgroup analyses of the NAPOLI‐1 study identified that among patients who were irinotecan naïve prior to entering the clinical trial, a survival benefit was observed between the study arm and control arm.
Kenneth H. Yu, Paul Cockrum, Andy Surinach, Neil Lamarre, Shu Wang, Eileen M. O'Reilly   +5 more
doaj   +1 more source

CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer.

PLoS ONE, 2020
Irinotecan specifically targets topoisomerase I (topoI), and is used to treat various solid tumors, but only 13-32% of patients respond to the therapy.
Hiroya Matsuoka, Koji Ando, Emma J Swayze, Elizabeth C Unan, Joseph Mathew, Quingjiang Hu, Yasuo Tsuda, Yuichiro Nakashima, Hiroshi Saeki, Eiji Oki, Ajit K Bharti, Masaki Mori   +11 more
doaj   +1 more source

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy

Therapeutic Advances in Medical Oncology, 2021
Introduction: Liposomal irinotecan (nal-IRI) plus fluorouracil/leucovorin (5-FU/LV) has shown clinical benefit in patients with metastatic pancreatic adenocarcinoma (mPAC) who progressed on gemcitabine-based chemotherapy.
Kyunghye Bang, Jaekyung Cheon, Jae Ho Jeong, Hyeon-Su Im, Kyu-pyo Kim, Baek-Yeol Ryoo, Changhoon Yoo   +6 more
doaj   +1 more source